Abstract | OBJECTIVE: METHODS: In this prospective multicenter therapeutic trial, 48 patients with CSS with at least 1 poor-prognosis factor at baseline were treated with glucocorticoids and either 12 or 6 intravenous cyclophosphamide pulses. RESULTS: At 8 years, complete remission rates and severe side effects of therapy were comparable for both groups. The overall difference in relapses was not significant between the 12-pulse and the 6-pulse regimens (P = 0.07), but when considering only the number of mild relapses this difference became statistically significant (P < 0.02). Although the total number of inclusions was not reached, the study was stopped prematurely in response to the superiority of the 12-pulse regimen. CONCLUSION:
|
Authors | Pascal Cohen, Christian Pagnoux, Alfred Mahr, Jean-Pierre Arène, Luc Mouthon, Véronique Le Guern, Marie-Hélène André, Martine Gayraud, David Jayne, Daniel Blöckmans, Jean-François Cordier, Loïc Guillevin, French Vasculitis Study Group |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 57
Issue 4
Pg. 686-93
(May 15 2007)
ISSN: 0004-3591 [Print] United States |
PMID | 17471546
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antirheumatic Agents
- Glucocorticoids
- Cyclophosphamide
|
Topics |
- Adult
- Aged
- Antirheumatic Agents
(administration & dosage, adverse effects)
- Churg-Strauss Syndrome
(drug therapy, mortality)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Female
- Glucocorticoids
(administration & dosage, adverse effects)
- Humans
- Injections, Intravenous
- Male
- Middle Aged
- Prognosis
- Prospective Studies
- Pulse Therapy, Drug
- Recurrence
- Survival Rate
- Treatment Outcome
|